|
|
Books > Medicine > Clinical & internal medicine > Diseases & disorders > Oncology > General
Interventional Oncology is a fast-growing new field, as well as an
emerging specialty. Many minimally-invasive, imaging-guided
procedures seem set to replace more traditional open surgical
techniques of treating solid tumors in a variety of organs. The aim
of this book is to describe new interventional radiological methods
in a succinct and practical form. Diagnostic radiological
considerations relevant to the selection and follow-up of patients
are also covered. The book begins with an overview of the basic
principles of current interventional techniques, including thermal
ablation, high intensity focused ultrasound, and embolization.
Later chapters focus on tumors of the liver, kidney, lung, and
bone, placing new interventional techniques in context by referring
to the surgical and oncologic methods of treating the same
conditions. With an emphasis on best practices, Interventional
Oncology: A Practical Guide for the Interventional Radiologist will
serve as a definitive guide to practicing physicians involved in
this rapidly evolving field.
The high rate of urbanization and a steady increase in per capita
income has improved the socio-economic status of people all over
the world. This has resulted in drastic changes in their lifestyle
and food consumption patterns, where traditional foods are being
replaced with more ready-made junk foods with few servings of fresh
vegetables and fruits. It has been postulated that
industrialization has caused change in food choice, dietary pattern
modification and resulted in a sedentary lifestyle. In addition,
contaminated foods with unsafe microbes and chemical hazards are
increasing. All of these events have resulted in an increased risk
of cancer, the leading cause of mortality and morbidity worldwide.
This book will provide a basic understanding of cancer, its risk
factors, preventive measures, and possible treatments currently
available, as well as identifying the different dietary factors
that might synergize with a sedentary lifestyle in the etiology of
cancer, and its prevention measure.
Nitric Oxide as a Chemosensitizing Agent, Volume One is the first
book to describe several reviews by authoritative scientists and
clinicians on novel findings in the reversal of drug resistant
cancers by the combination treatment of Nitric Oxide and sub toxic
concentrations of chemotherapeutic drugs that have been reported in
both in vitro, in vivo and preclinical models. The book describes
the various underlying chemical, molecular and genetic mechanisms
by which NO and NO reactive species mediate the anti-cancer
activity, thus reducing the threshold of drug resistance and
enabling chemo therapeutic drugs to induce their cytotoxic activity
and reversal of resistance. This book exposes scientists and
clinicians to this highly beneficial topic for research
investigations and pharmaceutical companies to new avenues for
R&D. It is a valuable resource for cancer researchers,
oncologists and members of several areas of the biomedical field
who are interested in understanding how to use Nitric Oxide as a
sensitizing agent for chemotherapy.
Role of Nutraceuticals in Chemoresistance to Cancer, Volume Two,
focuses on nutraceuticals, the compounds derived from natural
sources, which are usually multi-targeted as a means to overcome
chemoresistance. This book discusses the role of several compounds
related to nutraceuticals and chemoresistance, such as curcumin,
resveratrol, indole 3-carbinol, tocotrienols, ursolic acid,
fisetin, celastrol, gambogic, butein, catechins and silymarin. It
is a valuable resource for cancer researchers, oncologists and
members of several areas of the biomedical field who are interested
in understanding how to use nutraceuticals as a sensitizing agent
for chemotherapy.
This volume explores the latest techniques used to study tumor
immunology. The chapters in this book detail methodologies for
functional analysis and expansion of T lymphocytes for cancer
research. The chapters also cover topics such as how single-cell
RNA-sequencing can be exploited to dissect immune cell
heterogeneity and precursors; isolating and expanding natural
killer (NK) cells; evaluating NK cell-mediated anti-tumor killing
activity in vitro; immunosurveillance orchestrated by specific
immune subsets; use of HLA peptidomics for cancer-exome based
identification of tumor neo-antigens; gold standard assessment of
immunogenic cell death in oncological mouse models and methods to
look at the therapeutic relevance of immune modulation in cancer.
Written in the highly successful Methods in Molecular Biology
series format, chapters include introductions to their respective
topics, lists of the necessary materials and reagents,
step-by-step, readily reproducible laboratory protocols, and tips
on troubleshooting and avoiding known pitfalls. Cutting-edge and
thorough, Cancer Immunosurveillance: Methods and Protocols is a
valuable resource to aid researchers in better understanding and
experimenting in this exciting and developing field.
This volume explores the role of proteases in various catalytic
classes and cellular processes associated with cancer. The chapters
in this book cover topics such as encoding proteolytic enzymes,
cleavage sites of proteases, functional catalytic domains of MMPs,
zymography, angiogenesis and lymphangiogenesis, genetic and
epigenetic alterations of metallopeptidases, and methods to target
metalloproteinases. Written in the highly successful Methods in
Molecular Biology series format, chapters include introductions to
their respective topics, lists of the necessary materials and
reagents, step-by-step, readily reproducible laboratory protocols,
and tips on troubleshooting and avoiding known pitfalls.
Comprehensive and cutting edge, Proteases and Cancer: Methods and
Protocols is a valuable resource for clinical researchers across
numerous fields such as molecular and cellular biology, oncology,
biochemistry, and chemistry. This book is also useful for PhD
students in the various disciples of health sciences.
This thesis describes the authors' pioneering efforts in the
conceptualization and implementation of combined platinum-based
immuno-chemotherapeutics, which represent a significant paradigm
shift from the conventional approach of directly targeting cancer.
The work described has opened up a rich and largely unexplored area
for platinum-based drug design, and ultimately paves the way for
superior immuno-chemotherapeutics with better clinical outcome for
patients. Historically, the contribution of the immune system to
chemotherapy outcomes has been neglected, as anticancer drugs were
believed to be immunosuppressive. However, this has been challenged
by contemporary evidence suggesting that many chemotherapeutics,
including platinum-based agents, stimulate the innate and/or
adaptive immune system and that these "secret allies" contribute
tangibly to clinical outcomes. A multi-pronged
immuno-chemotherapeutic approach not only shrinks tumors, but more
importantly, reactivate dormant immune responses to malignancies,
eliminating residual cancer cells.
Over a period of almost 10 years, the work of the Project on Death
in America (PDIA) played a formative role in the advancement of end
of life care in the United States. The project concerned itself
with adults and children, and with interests crossing boundaries
between the clinical disciplines, the social sciences, arts and
humanities. PDIA engaged with the problems of resources in poor
communities and marginalized groups and settings, and it attempted
to foster collaboration across a range of sectors and
organizations. Authored by medical sociologist David Clark, whose
research career has focused on mapping, archiving and analyzing the
history and development of hospice, palliative care and related end
of life issues, this book examines the broad, ambitious conception
of PDIA - which sought to 'transform the culture of dying in
America' - and assesses PDIA's contribution to the development of
the palliative care field and to wider debates about end of life
care within American society. Chapters consider key issues and
topics tackled by PDIA grantees which include: explorations of the
meanings of death in contemporary American culture; the varying
experiences of care at the end of life (in different settings,
among different social and ethnic groups); the innovations in
service development and clinical practice that have occurred in the
US in response to a growing awareness of and debate about end of
life issues; the emerging evidence base for palliative and end of
life care in the US; the maturation of a field of academic and
clinical specialization; the policy and legal issues that have
shaped development, including the ethical debate about assisted
suicide and the Oregon experience; the opportunities and barriers
that have been encountered; and the prospects for future
development. A final chapter captures developments and milestones
in the field since PDIA closed in 2003, and some of the challenges
going forward.
Lung cancer is the neoplastic disease with the highest mortality numbers in the world. The disease is very common in industrialized countries. This textbook synthesizes the basic science of lung cancer with state-of-the-art accounts of diagnosis and treatment. Written by a distinguished panel of experts from Europe, Asia, and North America, it covers all of the most important fields: biology, pathology, epidemiology, screening, diagnosis, therapy, supportive care, and prognosis. All physicians caring for patients with lung cancer, especially surgeons, chest physicians, radiation oncologists, and medical oncologists, will find a wealth of information that meets their needs. Whenever possible, the principles of evidence-based medicine are followed by providing data from systematic reviews, meta-analyses, methodology-based guidelines, and randomized clinical trials.
Targeting Cell Survival Pathways to Enhance Response to
Chemotherapy encompasses recently developed molecular targeting
agents and approaches that suppress cell survival signaling. Cell
survival signaling attenuates the effectiveness of conventional
chemotherapy and numerous mechanisms have been described, and
continue to be described, which contribute to cell survival in the
face of chemotherapy treatment. Key pathways leading to
chemoresistance emanate from growth factor receptors, PI3K, STAT3,
anti-apoptotic Bcl-2 family members, autophagy, and the DNA damage
response pathway. New advances have underscored the potential of
targeting each of these cell survival mechanisms to improve
responsiveness to chemotherapy. This book reviews these recent
advances and provides a foundational background and hints of new
opportunities for basic, translational, and clinical investigators
focused on improving therapeutic responses to chemotherapy.
This thesis describes the design, development, characterisation and
clinical translation of three novel devices for optical endoscopic
imaging. Over the past decade, rapid innovation in optics and
photonics has led to the availability of low-cost and
high-performance optical technologies that can be exploited for
biomedical applications, but relatively few have been translated
into clinic. The work presented outlines for the first time, a
comprehensive analysis of the common barriers and unique challenges
associated with the translation of optical imaging techniques. To
assist developers streamline translation of optical imaging devices
in future, a roadmap to clinical translation is outlined, and key
translational characteristics are defined. Guided by these,
subsequent development of endoscopic devices resulted in
preparation and approval of endoscopes for first in human trials in
the oesophagus, for early detection of cancer, and in the brain,
for delineation of tumour during surgical resection. The thesis
culminates in the presentation of results from the first in human
use of a compact multispectral endoscope for imaging endogenous
tissue contrast in the oesophagus. With continuation of the work as
outlined at the end of this thesis, the novel techniques described
have the potential to improve the standard of care in their
respective indications.
Get a quick, expert overview of the many key facets of lung cancer
evaluation and management with this concise, practical resource by
Drs. Lynn T. Tanoue and Frank Detterbeck. This easy-to-read
reference presents a summary of today's best evidence-based
approaches to diagnosis and management in this critical area.
Get a quick, expert overview of clinically-focused topics and
guidelines that are relevant to testing for HER2, which contributes
to approximately 25% of breast cancers today. This concise resource
by Drs. Sara Hurvitz, and Kelly McCann consolidates today's
available information on this growing topic into one convenient
resource, making it an ideal, easy-to-digest reference for
practicing and trainee oncologists. Covers the diagnosis,
treatments and targeted therapies, and management of breast cancers
that are HER2-positive. Contains sections on background and
testing, advanced disease, therapeutics, and toxicity
considerations. Includes a timely section on innovative future
therapies.
This issue of Hematology/Oncology Clinics, edited by Dr. Janet
Abrahm, focuses on Pain Control. Topics include, but are not
limited to, Complex pain assessment; Evidence-based
non-pharmacologic therapies; Non-opioid pharmacologic therapies;
Opioid caveats, newer agents, and prevention/management of side
effects and of aberrant use; Cancer pain syndromes; Agents for
neuropathic pain RX; Mechanism of and Adjuvants for bone pain;
Interventional anesthetic methods; Radiation therapy methods;
Rehabilitation methods; Psychological treatment; Spiritual
considerations; Pain in patients with SS diseases; and Pain in HSCT
patients.
Advances in Cancer Research, Volume 139, provides invaluable
information on the exciting and fast-moving field of cancer
research. Original reviews are presented on a variety of topics
relating to the rapidly developing intersection between
nanotechnology and cancer research, with unique sections in the new
release focusing on Exosomes as a theranostic for lung cancer,
Nanotechnology and cancer immunotherapy, Ultrasound imaging agents
and delivery systems, Dendronized systems for the delivery of
chemotherapeutics, Thermosensitive liposomes for image-guided drug
delivery, Supramolecular Chemistry in Tumor Analysis and Drug
Delivery, Gold nanoparticles for delivery of cancer therapeutics,
and Single cell barcode microchip for cancer research and therapy.
This issue of PET Clinics focuses on Lung Cancer, and is edited by
Drs. Gang Cheng and Timothy Akhurst. Articles will include: FDG
PET/CT for lung cancer staging; Lung neoplasms with low FDG
avidity; FDG PET/CT evaluation of lung cancer in populations with
high prevalence of granulomatous disease; Prognostic value of FDG
PET/CT; Genomic characterization of lung cancer and its impact on
the use and timing of PET in therapeutic response assessment;
Treatment planning for radiation therapy; Future directions of PET
imaging for lung cancer; PET for RT-planning in lung cancer;
Genomic characterization of lung cancer and its impact on the use
and timing of PET in therapeutic response assessment; and more!
This volume evaluates the clinical patterns of resistance to
sorafenib, the impact of trial design in the second-line setting
and the current gold standard to define radiological resistance;
describes the molecular mechanisms responsible for treatment
resistance in HCC patients, including components of the immune
system and tumor microenvironment; determines the role of the
cancer stem cell phenotype in resistance; reviews the experimental
models to study resistance; and addresses new approaches to
overcome resistance to sorafenib, using successful examples from
other malignancies.
|
|